Skip to main content

Arcadia Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 26, 2026

RKDA$0.17+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

TABLE OF CONTENTS FOR FORM 10-K

Page
PART I
Item 1.Business2
Item 1A.Risk Factors4
Item 1B.Unresolved Staff Comments11
Item 1C.Cybersecurity12
Item 2.Properties12
Item 3.Legal Proceedings12
Item 4.Mine Safety Disclosures13
PART II
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities14
Item 6.[Reserved]14
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations15
Item 7A.Quantitative and Qualitative Disclosures About Market Risk25
Item 8.Financial Statements and Supplementary Data26
Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure61
Item 9A.Controls and Procedures62
Item 9B.Other Information63
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections63
PART III
Item 10.Directors, Executive Officers and Corporate Governance64
Item 11.Executive Compensation64
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters64
Item 13.Certain Relationships and Related Transactions, and Director Independence64
Item 14.Principal Accounting Fees and Services64
PART IV
Item 15.Exhibits, Financial Statement Schedules65

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.